Oct 17, 2014
“Any knock-on effect from the AbbVie board's recommendation against the Shire deal should be limited to other deals similarly structured to access offshore cash and extensively restructure offshore holdings. Many transactions that would not depend on these tax-planning techniques are still good candidates for an inversion.”
- Linda Z. Swartz, Chair of the Tax group at Cadwalader, commenting in Law360 on the effect of the Treasury’s new anti-inversion rules on pending and future inversion transactions.
Scott Cammarn, Mark Chorazak
Joseph Moreno, Jodi Avergun, Andrew Alin, Joshua Apfelroth, Keith Gerver